Trial Profile
A phase 1/2 study of PXL01 for prevention of dermal scarring
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Ensereptide (Primary)
- Indications Scars
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2018 New trial record
- 03 Sep 2018 According to a Promore Pharma media release, this study will be performed in Sweden and co-ordinated by Fredrik Huss, Associate Professor in Plastic Surgery at Uppsala University.